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TTP and OS were female gender, the absence of smoking history, and 
adenocarcinoma histology. As expected, those treated with Erlotinib in 
the ﬁrst line setting had signiﬁcantly longer TTP than further lines (7.4 
vs. 4.4; p<0.001). In the multivariate analysis only non smoking history 
remained as predictive factor for longer TTP and survival (p<0.0001). 
Most frequent reported adverse events were rash (62.9%; 12.9% grade 
3/4), asthenia (37.1%; 9.2% grade 3/4) and diarrhea (33.3%; 6.1% 
grade 3/4).
Conclusions: This interim analysis of a subset of elderly patients with 
advanced or metastatic NSCLC treated with Erlotinib in a real-life 
clinical setting conﬁrms the good tolerability and promising activity. It 
is worthwhile mentioning the beneﬁt in survival obtained by chemona-
ïve elderly patients. Therefore Erlotinib is an effective treatment for 
elderly patients with advanced NSCLC, even as a ﬁrst-line treatment. A 
randomized phase III study intended for elderly patients with Erlotinib 
is warranted.
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Background: Erlotinib, a tyrosine kinase inhibitor, has been shown to 
improve the survival and quality of life in patients with non-small cell 
lung cancer (NSCLC) after ﬁrst or second-line chemotherapy. Asian 
origin, adenocarcinoma histologic type, female gender, lack of tobacco 
use, and expression of EGFR have been described as signiﬁcant inde-
pendent predictors of response to erlotinib. Although tobacco use is 
considered a major cause of NSCLC, other factors are involved in its 
pathogenesis. In underdeveloped countries such as Mexico, wood and 
other solid fuels are still used for cooking and heating. The pathophysi-
olocial mechanisms of wood smoke exposure (WSE) as a potential risk 
factor for the development of NSCLC are still unknown. 
Methods: In this study, 135 patients with histologically proven NSCLC 
with poor performance status were treated with erlotinib after ﬁrst or 
second-line chemotherapy. Clinical and pathological characteristics 
were associated with response to treatment. 
Results: We found a global response to erlotinib in 45 patients (31.3%, 
CI 95% 23.5-39.1), stable disease in 31.9% and progression in 30.6%. 
Clinical improvement was observed in 56.5%. The clinical features 
associated with response to erlotinib in the univariate analysis were 
female gender (44.4 vs. 20.6%, p=0.003), no tobacco use (48.4 vs. 
19.7%, p<0.001). Borderline statistical signiﬁcance was observed with 
adenocarcinoma histological type (34.3 vs. 16%, p=0.086). However, 
in the logistic regression analysis only the histological type (p=0.049) 
and WSE (p=0.001) showed statistical signiﬁcance. The factors as-
sociated to an improved progression-free survival(PFS) in the Cox 
multivariate analysis were adenocarcinoma histologic type (7.9±0.7 vs 
2.2±0.4 months, p= 0.02), female gender (8.4±0.7 vs 4.4±1.6 months, 
p= 0.02) and WSE (17.56±4.17 vs 4.8±0.7 months, p< 0.001). 
Conclusion: WSE is associated with response to erlotinib in patients 
with NSCLC and may indicate an improvement in PFS. The EGFR 
mutation is probably involved in the development of NSCLC in non-
smokers with WSE. 
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Background: IL-20 is a pleiotrophic member of the IL-10 family and 
plays a role in skin inﬂammation and the development of haematopoi-
etic cells. It has potent angiogenic, inﬂammatory and chemo-attrac-
tive characteristics with an involvement in rheumatoid arthritis and 
atherosclerosis. It activates STAT3, which in turn promotes prolifera-
tion, apoptosis resistance and immune tolerance. STAT3 activation 
is recognised as an important link between inﬂammation and cancer. 
It can function through IL-20Rα, IL-20Rβ and IL-22R1. Decreased 
expression of IL-20Rα in lung tissues of non-small lung cancer patients 
correlated with an increase in disease free survival. 
Methods: A panel of cell lines were examined for the expression of 
IL-20, IL-20Rα and IL-20Rβ at the mRNA and protein level. This 
included three normal (HBEC 3, 4 & 5) and two lung cancer (A549-
adenocarcinoma & SK-MES-1- squamous cell carcinoma) cell lines. 
The effects of a histone deacetylase inhibitor, Trichostatin A, (TSA-
250ng/ml) and cycloheximide (10μg/ml) on the expression of the IL-20 
family were examined. A CHiP assay was carried out to investigate 
the effect of TSA on the IL-20 promoter. Tumour and normal matched 
tissue from patients were examined at the mRNA and protein level for 
the IL-20 receptors. 
Results: The mRNA expression pattern of IL-20 was different in the 
normal and lung cancer cell lines. There was moderate to high expres-
sion in the three normal cell lines compared with low to moderate lev-
els in the cancer cell lines. A similar trend was observed with IL-20Rα 
and IL-20Rβ. The anti-angiogenic properties of IL-20 have previously 
been demonstrated in the lung. We investigated the effect of TSA on 
IL-20 expression. IL-20 was induced by TSA treatment in all cell lines 
and super-induced by cycloheximide in A549 and HBEC 4. Results 
from a CHiP assay performed on A549 cells demonstrates that the ef-
fect of TSA is and early and immediate response. The effect of TSA on 
the two receptors at mRNA level was much less pronounced on the cell 
lines with the exception of HBEC 4, which showed a minor increase 
of both with treatment. Further analysis of IL-20 and the receptors in 
clinical (adenocarcinoma and squamous cell carcinoma) samples re-
vealed a somewhat different pattern between the two lung cancer types. 
At the mRNA level, IL-20 was downregulated in adenocarcinoma and 
upregulated in squamous samples. There was an increase in IL-20Rβ 
mRNA and protein in both tumour types. A signiﬁcant difference 
was observed in IL-20Rα expression between the tumour types. In 
adenocarcinomas, IL-20Rα was predominantly downregulated at the 
mRNA level, with minimum detection at the protein level. However, in 
squamous samples the receptor was upregulated in tumours at both the 
mRNA and protein level. 
Copyright © 2007 by the International Association for the Study of Lung Cancer S705
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Conclusions: An IL-20 ELISA has been developed and further samples 
are being collected for analysis. Based on these ﬁndings that IL-20 is 
up-regulated by TSA and under epigenetic control, targeting this cy-
tokine may be used as a potential anti-angiogenic approach in making 
lung cancer history.
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A number of growth-factor-receptor-targeted agents have been tried 
with encouraging results in patients with advanced NSCLC (Noble et 
al 2006). Women, non-smokers, adenocarcinoma and Asians respond 
better. This communication is our further experience of our earlier 
presentation. 
Histologically proven advanced (stage IIIB or IV) non-small cell lung 
cancer patients earler treated with chemotherapy received geﬁtinib 
(Geﬁtinat) 250mg daily orally. There were 28 females (38-57 yrs) and 
67 males (44-67 yrs). Fifty four were non-smokers and the remaining 
were smokers. Sixty two had adenocarcinoma and 33 had squamous 
cell carcinoma. The disease was of stage IIIB (n=58) and stage IV 
(n=37). The duration of geﬁtinib therapy varied from 20 weeks to 58 
weeks with median of 29.5 weeks. The disease remained static in 66 
(69%) with stabilization or improvement in the Kornofsky performance 
scales in 73. The mean performance status improved from 70 to 90 
in 34 cases, deteriorated in 13 and in the remaining remained static at 
90. There was no radiological progression in 43 cases, while 28 cases 
showed radiological progression. The median survival (calculated after 
completion of chemotherapy and start of geﬁtinib) was 33 weeks with 
22 patients surviving beyond 1 year. The drug was well tolerated by 
all. Thirty three patients complained of mild skin rash (three ﬁxed drug 
eruption). 29 patients had grade 1-2 diarrhoea. 
We found geﬁtinib as beneﬁcial The drug is well tolerated by Indian 
patients.This may be due to a different pharmacogenomic property of 
geﬁtinib in this population. 
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Background: VEGF expression has been correlated with increased 
tumor angiogenesis and shortened survival in NSCLC, and inhibition 
of the VEGF and also the EGF signaling pathways has a demonstrated 
treatment beneﬁt in this malignancy. Therefore, a treatment strategy 
combining agents that speciﬁcally inhibit both signaling pathways may 
further improve patient outcome. Sunitinib malate is an oral, multitar-
geted tyrosine kinase inhibitor of VEGFRs, PDGFRs, KIT, RET and 
FLT3, approved multinationally for the treatment of advanced renal cell 
carcinoma and imatinib-resistant or -intolerant gastrointestinal stromal 
tumor. A multicenter phase II trial of sunitinib administered on a 4/2 
schedule (4 weeks on treatment followed by 2 weeks off) in recurrent 
advanced NSCLC demonstrated an 11% objective response rate among 
patients treated second- or third-line (Socinski, ESMO 2006). Here 
we report the results of a lead-in safety study assessing the safety and 
tolerability of sunitinib combined with erlotinib in locally advanced or 
metastatic NSCLC after failure of chemotherapy. If the safety proﬁle 
of the combination is favorable, 126 patients will be randomized to 
sunitinib plus erlotinib or to placebo plus erlotinib in a phase II portion 
of the study.
Methods: The lead-in safety cohort was planned to include 10 patients 
evaluable for the safety and tolerability of sunitinib combined with 
erlotinib, with additional patients enrolled if needed to obtain adequate 
pharmacokinetic data. Patients were eligible if they had histologically 
proven, stage IIIB or IV NSCLC; had received 1 or 2 prior chemothera-
py regimens, including a platinum-based regimen; measurable disease; 
ECOG PS 0 or 1, and adequate organ function. Treatment comprised 
sunitinib 37.5 mg/day continuously plus erlotinib 150 mg/day, given 
orally, in repeated 4-week cycles. Patients were observed for dose-lim-
iting toxicities (DLTs) during the ﬁrst 28 days of treatment.
Results: Twelve patients were treated in the lead-in cohort, with the 
following baseline characteristics: median age 62 years (range 47-75); 
6 male; histology 9 adenocarcinoma, 1 squamous cell carcinoma, 2 
other; history of smoking in 8 patients. The patients started a median of 
2 cycles (range 1-5), with dose reductions in 5 patients (erlotinib, n=2; 
sunitinib, n=1; both, n=2). Two patients developed a DLT (both grade 3 
fatigue lasting at least 7 days). Adverse events were generally mild-to-
moderate in severity (grade 1/2). Seven patients experienced grade 3 
adverse events that included diarrhea (n=3), fatigue (n=2), acne (n=1), 
anemia (n=1), dehydration (n=1), diffuse skin rash (n=1), pruritus 
(n=1) and paronychial inﬂammation (n=1); no grade 4/5 events were 
reported. Pharmacokinetic analyses are ongoing.
Conclusions: Sunitinib 37.5 mg/day given continuously with erlo-
tinib 150 mg/day was safe and tolerable in this cohort of patients with 
advanced NSCLC. The efﬁcacy and safety of sunitinib combined with 
erlotinib will be investigated further in the randomized phase II portion 
of this study. 
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Background: In non-small cell lung cancer (NSCLC) preclinical 
models, celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, potentiates 
the apoptotic and growth inhibitory effects of erlotinib, an epidermal 
growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). We 
designed a phase II trial to evaluate the clinical efﬁcacy and safety of 
erlotinib plus celecoxib in advanced NSCLC. 
